BBBinukumar Bk

Binukumar Bk

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Binukumar Bk has a total of 161 co-authors. Here are the top co-authors by number of shared publications:

  • Harish C. Pant

    Neuronal Cytoskeletal Protein Regulation Section, National Institute of Neurological Disorders and Stroke, Bethesda, MD 20824, USA

    9 shared publications
  • Sangita Paul

    CSIR Institute of Genomics and Integrative Biology, New Delhi, India

    9 shared publications
  • Niranjana D. Amin

    Neuronal Cytoskeletal Protein Regulation Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA

    8 shared publications
  • Varsha Shukla

    National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA

    7 shared publications
  • Juhi Bhardwaj

    6 shared publications
  • Philip Grant

    National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA

    6 shared publications

Latest Publications

  • Open Access

    Lepr Haploinsufficiency Accelerates Alzheimer-like Neurodegeneration via CDK5 Hyperactivation

    by Sangita Paul, Juhi Bhardwaj, Srishti Sharma, Mohammed Swalih, Deepanshi Koul, Binukumar Bk

  • Open Access

    Heterozygous Lepr Mutation Accelerates Alzheimer-like Neurodegeneration in db/+ Mice via CDK5 Hyperactivation

    by Sangita Paul, Juhi Bhardwaj, Srishti Sharma, Kt Mohammed Swalih, Deepanshi Koul, B.K. Binukumar

    Leptin signaling has neuroprotective effects and is increasingly linked to Alzheimer’s disease (AD). Beyond metabolism, leptin modulates β-amyloid metabolism, tau phosphorylation, and synaptic plasticity. While homozygous Lepr mutations are well studied, the impact of heterozygous mutations on neurodegeneration is unclear. To assess partial Lepr loss, one-year-old db/+ mice were evaluated for metabolic, behavioral, and neuropathological changes. Tests included glucose tolerance, memory assays, Aβ 42 and tau levels, CDK5 activity, and transcriptomics. Human LEPR variants were curated and classified using ACMG guidelines. Aged db/+ mice showed metabolic dysfunction, cognitive deficits, and AD-like pathology. Compared to controls, db/+ mice had increased body weight, insulin resistance, memory impairments, elevated Aβ 42 , tau hyperphosphorylation, CDK5 hyperactivation, and astrocyte activation. Transcriptomics revealed altered synaptic and mitochondrial pathways. Thirty-three pathogenic or likely pathogenic human LEPR variants were identified. Lepr haploinsufficiency contributes to age-related cognitive decline and AD-like pathology, suggesting it as a genetic risk factor and therapeutic target.

  • Open Access

    Genetic Spectrum of Autism Spectrum Disorder Associated Variants in the Indian Population: Insights from 1,029 IndiGenomes

    by Mukesh Kumar, Treesa Issen, Mohammed Swalih, Srishti Sharma, Sheffali Gulati, Sridhar Sivasubbu, Vinod Scaria, Bk Binukumar

    Background: Autism spectrum disorder (ASD) is a lifelong neurodevelopmental condition characterised by social and behavioural challenges. It is highly heritable, with estimates ranging from 40-90% and a liability-scale heritability of 0.924, underscoring the role of genetic variants in its pathogenesis. Limited studies from India hinder an accurate assessment of the country’s true ASD genetic spectrum. Aim: To investigate the genetic spectrum in an Indian control dataset, providing baseline variant frequency data to facilitate interpretation of disease-associated variants in the Indian population. Methods: We compiled a strongly ASD-linked gene panel from the SFARI and ClinGen databases, followed by the extraction of gene-associated variants from the IndiGenomes dataset. A stepwise analysis pipeline was implemented, including variant annotation, filtering for minor allele frequency (MAF < 5%), prediction of deleteriousness using REVEL (>0.75), and loss-of-function prediction with LoFTEE (high confidence). Variants were then classified according to ACMG-AMP guidelines. Results: We identified 1,531,327 variants from 517 ASD panel genes (MAF < 5%) spanning ∼88 Mb of genomic regions. ACMG-AMP interpretation was performed for prioritised 298 missense variants (REVEL > 0.75) and 537 LoF variants (LoFTEE; high confidence). Missense and LoF variants contributed 37% and 63% of the filtered data, respectively. Fifty-five variants from 28 genes were classified as pathogenic/likely pathogenic, while 10 variants in 6 genes showed significantly higher MAF (p < 0.05; Fisher’s exact test). Carrier numbers were estimated for autosomal recessive inheritance models. Conclusion: This study provides a comprehensive spectrum of ASD-related genetic variants in the Indian population, offering valuable insights for ASD diagnosis, genetic interpretation, and understanding of underlying molecular mechanisms.

  • Open Access

    A Cdk5 inhibitor restores cognitive function and alleviates type 2 diabetes in mice

    by Sangita Paul, Remya Chandran, Dileep K. Vijayan, Juhi Bhardwaj, Praveen Singh, Poornima Shetty, Srinivas Cheruku, Sajith Meleveetil, Binukumar Balachandran Krishnamma


  • Open Access

    Exploring New Horizons: A Novel Cdk5 Inhibitor Restoring Cognitive Function and Alleviating Type 2 Diabetes

    by Sangita Paul, Chandran Remya, K.V. Dileep, Juhi Bhardwaj, Praveen Singh, S Poornima, C Srinivas, A.M. Sajith, Bk Binukumar, Poornima Poornima Shetty

    Type 2 diabetes (T2D) is a metabolic disorder frequently associated with cognitive decline, making T2D patients susceptible to dementia. Often referred to as type 3 diabetes, Alzheimer’s disease (AD) shares a close association with hyperglycemia and insulin dysregulation. Despite this, anti-diabetic medications have proven beneficial in reducing cognitive impairment induced by T2D. Previous research, including our own, has highlighted the dysregulation of Cdk5 activity in both T2D and AD, with downstream consequences contributing to the progression of pathophysiological changes in both disorders. Therefore, targeting the kinase Cdk5 may offer a more effective approach to treating T2D and cognitive deterioration. In our study, we present evidence supporting Cdk5 as a significant mediator between T2D and cognitive decline. Through the screening of the KINACore library, we identified novel brain-penetrant Cdk5 inhibitors, BLINK11 and BLINK15. Our study further validated the efficacy of these inhibitors in a high-fat diet-induced T2D model, demonstrating their rescue effects on T2D pathogenesis, including blood glucose levels, obesity, and cognitive impairment as assessed through behavioral studies. Notably, BLINK11 emerges as a promising Cdk5 inhibitor for improving the T2D phenotype and addressing cognitive impairment in T2D conditions. Graphical

  • Open Access

    Unprecedented Co-occurrence: Identification of a Pathogenic Genetic Variant in the KMT2B Gene in a Wilson Disease Patient with a Pathogenic ATP7B Mutation

    by Mukesh Kumar, Aminu Aliyar, Arti Saini, Sridhar Sivasubbu, Vinod Scaria, Divya M Radhakrishnan, Roopa Rajan, Binukumar Bk

    The pathophysiology of dystonia in Wilson disease (WD) is complex and poorly understood. Copper accumulation in the basal ganglia, disrupts dopaminergic pathways, contributing to dystonia’s development via neurotransmitter imbalance. Despite advances in diagnosis and management, WD with dystonia remains a challenging condition to treat. We aim to report the unprecedented co-occurrence of pathogenic genetic variants in both the ATP7B and KMT2B genes in a patient with WD. A 13-year-old male presented at 12 with dysarthria and bilateral Kayser-Fleischer rings. Over months, dystonia spread to his left foot, upper limb, and trunk, accompanied by slowed daily activities. Diagnostic tests included MRI for brain structure, abdominal ultrasound for liver function, serum ceruloplasmin and copper levels to assess copper metabolism, and 24-hour urine copper tests for excretion levels. Whole exome sequencing was conducted using genomic DNA from peripheral blood samples. Variant classification followed guidelines from the American College of Medical Genetics and Genomics. The sequencing revealed compound heterozygous pathogenic variants in the ATP7B gene: NM_000053.4:c.2165dupT and NM_000053.4:c.813C>A. A pathogenic variant in the KMT2B gene, NM_014727:c.3052delA, was identified. This case highlights WD co-occurrence with ATP7B and KMT2B mutations, suggesting KMT2B as a potential genetic modifier.


  • Open Access

    WilsonGenAI a deep learning approach to classify pathogenic variants in Wilson Disease

    by Aastha Vatsyayan, Mukesh Kumar, Bhaskar Jyoti Saikia, Vinod Scaria, Binukumar B K

    Background: Advances in Next Generation Sequencing have made rapid variant discovery and detection widely accessible. To facilitate a better understanding of the nature of these variants, American College of Medical Genetics and Genomics and the Association of Molecular Pathologists (ACMG-AMP) have issued a set of guidelines for variant classification. However, given the vast number of variants associated with any disorder, it is impossible to manually apply these guidelines to all known variants. Machine learning methodologies offer a rapid way to classify large numbers of variants, as well as variants of uncertain significance as either pathogenic or benign. Here we classify ATP7B genetic variants by employing ML and AI algorithms trained on our well-annotated WilsonGen dataset. Methods: We have trained and validated two algorithms: TabNet and XGBoost on a high-confidence dataset of manually annotated, ACMG & AMP classified variants of the ATP7B gene associated with Wilson’s Disease. Results: Using an independent validation dataset of ACMG & AMP classified variants, as well as a patient set of functionally validated variants, we showed how both algorithms perform and can be used to classify large numbers of variants in clinical as well as research settings. Conclusion: We have created a ready to deploy tool, that can classify variants linked with Wilson’s disease as pathogenic or benign, which can be utilized by both clinicians and researchers to better understand the disease through the nature of genetic variants associated with it.